Buy Viloxazine (Qelbree) Cas 46817-91-8
Viloxazine, sold under the brand name Qelbree among others, is a selective norepinephrine reuptake inhibitor medication that is indicated in the treatment of attention deficit hyperactivity disorder (ADHD) in children and adults.[1][5] It was marketed for almost 30 years as an antidepressant for the treatment of depression before being discontinued and subsequently repurposed as a treatment for ADHD.[6][5][1] Viloxazine is taken orally.[1] It was used as an antidepressant in an immediate-release form and is used in ADHD in an extended-release form,[6][1] although current evidence indicates that it is significantly less effective at reducing ADHD symptoms compared to stimulant medications like methylphenidate.[7][8]
Side effects of viloxazine include insomnia, headache, somnolence, fatigue, nausea, vomiting, decreased appetite, dry mouth, constipation, irritability, increased heart rate, and increased blood pressure.[1] Rarely, the medication may cause suicidal thoughts and behaviors.[1] It can also activate mania or hypomania in people with bipolar disorder.[1] Viloxazine acts as a selective norepinephrine reuptake inhibitor (sNRI).[6][1][5] The immediate-release form has an elimination half-life of 2.5 hours[6][2] while the half-life of the extended-release form is 7 hours.[1]
Viloxazine was first described by 1972[9] and was marketed as an antidepressant in Europe in 1974.[6][10] It was not marketed in the United States at this time.[11] The medication was discontinued in 2002 for commercial reasons.[6][12][13] However, it was repurposed for the treatment of ADHD and was reintroduced, in the United States, in April 2021.[6][14][15] Viloxazine is a non-stimulant medication; it has no known misuse liability and is not a controlled substance.[1]
Medical uses
Attention deficit hyperactivity disorder
Viloxazine is indicated to treat attention deficit hyperactivity disorder (ADHD) in children age 6 to 12 years, adolescents age 13 to 17 years, and adults.[1]
Analyses of clinical trial data suggest that viloxazine produces moderate reductions in symptoms; it is about as effective as atomoxetine and methylphenidate but with fewer side effects.[7][8][16]
Depression
Viloxazine was previously marketed as an antidepressant for the treatment of major depressive disorder.[6][5] It was considered to be effective in mild to moderate as well as severe depression with or without co-morbid symptoms.[6] The typical dose range for depression was 100 to 400 mg per day in divided doses administered generally two to three times per day.[6]
Available forms
Viloxazine is available for ADHD in the form of 100, 150, and 200 mg extended-release capsules.[1] These capsules can be opened and sprinkled into food for easier administration.[1]
Reviews
There are no reviews yet.